Hence, the current study provides a rationale for the testing of CHK1 inhibitors or other therapy strategies that interfere with CHK1 function in combination with gemcitabine in gemcitabine-naïve UC patients, in particular for patients with advanced and/or metastatic disease who are ineligible for cisplatin. The gene discussed is CHEK1; the disease is metastatic neoplasm.